Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Ben-Menachem E, et al. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. Epilepsy Res. 2021. PMID: 33461041 Free article. Clinical Trial.
This long-term open-label extension (OLE) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized doses in patients with epilepsy and focal (partial-onset) or generalized onset seizures, or Unverricht-Lundborg disease ( …
This long-term open-label extension (OLE) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) …
A Multicenter, Cross-Sectional, Observational Study on Epilepsy and its Management Practices in India.
Mehndiratta MM, Kukkuta Sarma GR, Tripathi M, Ravat S, Gopinath S, Babu S, Mishra UK. Mehndiratta MM, et al. Neurol India. 2022 Sep-Oct;70(5):2031-2038. doi: 10.4103/0028-3886.359162. Neurol India. 2022. PMID: 36352605 Free article.
BACKGROUND: Although epilepsy is a common neurological condition, there is paucity of nationwide data on treatment patterns and sociodemographic and clinical factors affecting treatment decisions in India. OBJECTIVE: To assess clinical profiles, usage pattern of ant …
BACKGROUND: Although epilepsy is a common neurological condition, there is paucity of nationwide data on treatment patterns and sociodemogra …
Carbamazepine versus phenobarbitone monotherapy for epilepsy.
Tudur Smith C, Marson AG, Williamson PR. Tudur Smith C, et al. Cochrane Database Syst Rev. 2003;(1):CD001904. doi: 10.1002/14651858.CD001904. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2015 Jul 23;(7):CD001904. doi: 10.1002/14651858.CD001904.pub2. PMID: 12535420 Updated. Review.
Carbamazepine is recommended as the drug of choice for partial onset seizures, and there is concern that it may worsen some generalized onset seizure types. We report a review using individual patient data in which carbamazepine and phenobarbitone are compare …
Carbamazepine is recommended as the drug of choice for partial onset seizures, and there is concern that it may worsen some generalized …
The diversity of seizures related to alcohol use. A study of consecutive patients.
Bråthen G, Brodtkorb E, Helde G, Sand T, Bovim G. Bråthen G, et al. Eur J Neurol. 1999 Nov;6(6):697-703. doi: 10.1046/j.1468-1331.1999.660697.x. Eur J Neurol. 1999. PMID: 10529758
Indications of partial onset seizures were found in 25 (51%) of AUDIT-positive patients, all secondarily generalized seizures. Sixty percent of generalized onset seizure patients were AUDIT-positive. In conclusion, seizure patients included significantly more …
Indications of partial onset seizures were found in 25 (51%) of AUDIT-positive patients, all secondarily generalized seizures. Sixty percent …